Our findings are in line with previous observations that although the efficacy of different mono-targeting therapies is often improved by their combination35, 36, the versatility of bi- or multi-targeting formats provide opportunities for the enhancement of cancer therapies via simultaneous engagement of more than one cell surface receptor. This evidence concerns the gene CD177 and cancer.